Tidal Investments LLC Raises Position in Astrazeneca Plc $AZN

Posted by Brian Himes on Sep 10th, 2026

Tidal Investments LLC boosted its holdings in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 14.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 248,108 shares of the company’s stock after buying an additional 31,379 shares during the period. Tidal Investments LLC’s holdings in Astrazeneca were worth $46,554,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Archford Capital Strategies LLC bought a new position in Astrazeneca in the second quarter valued at $498,000. Cidel Asset Management Inc. purchased a new stake in Astrazeneca during the 2nd quarter valued at about $44,480,000. Capital Analysts LLC grew its position in Astrazeneca by 18.2% during the 2nd quarter. Capital Analysts LLC now owns 962 shares of the company’s stock worth $181,000 after acquiring an additional 148 shares during the last quarter. SVB Wealth LLC purchased a new position in Astrazeneca in the 2nd quarter worth approximately $532,000. Finally, NorthRock Partners LLC increased its stake in Astrazeneca by 3.7% in the 2nd quarter. NorthRock Partners LLC now owns 3,462 shares of the company’s stock worth $657,000 after purchasing an additional 123 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

AZN has been the subject of a number of analyst reports. Bank of America reissued a “buy” rating on shares of Astrazeneca in a research note on Wednesday, July 1st. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Friday, June 26th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 30th. Barclays reissued a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. Finally, HSBC lowered shares of Astrazeneca from a “buy” rating to a “hold” rating in a report on Monday, July 13th. Fourteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $206.67.

Read Our Latest Analysis on Astrazeneca

Key Stories Impacting Astrazeneca

Here are the key news stories impacting Astrazeneca this week:

Positive Sentiment: Tozorakimab strengthens COPD growth outlook. Full phase III data presented at the European Respiratory Society Congress showed AstraZeneca’s experimental drug reduced COPD flare-ups across a broad range of patients. Citi said the results support a peak-sales opportunity of at least $7 billion—roughly twice consensus estimates—while AstraZeneca has previously outlined a forecast above $5 billion. AstraZeneca COPD data back Citi’s $7b peak sales case
Positive Sentiment: Additional late-stage COPD evidence supports blockbuster potential. Two successful late-stage trials and benefits across patient subgroups improve the prospects for regulatory approval and commercial adoption of tozorakimab, potentially adding a significant growth driver to AstraZeneca’s respiratory portfolio. AstraZeneca’s COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
Positive Sentiment: Imfinzi combination succeeds in small-cell lung cancer. AstraZeneca said Imfinzi combined with Amgen’s Imdelltra significantly improved overall survival in first-line extensive-stage small-cell lung cancer, expanding the potential value of its oncology franchise. AstraZeneca’s cancer drug combo hits main survival goal in late-stage trial
Neutral Sentiment: Trading remains weak despite the positive pipeline news. Market coverage reported that AZN underperformed the market on both Tuesday and Wednesday. The reports described the stock’s performance but did not identify a specific new company-related negative catalyst, suggesting investors may be digesting the news, taking profits, or responding to broader market conditions. AstraZeneca slips Wednesday, underperforms market

Astrazeneca Stock Performance

NYSE:AZN opened at $156.89 on Thursday. The stock has a market cap of $243.32 billion, a P/E ratio of 23.45, a price-to-earnings-growth ratio of 1.36 and a beta of 0.25. The firm’s fifty day simple moving average is $167.51 and its 200 day simple moving average is $183.14. Astrazeneca Plc has a twelve month low of $145.79 and a twelve month high of $212.71. The company has a quick ratio of 0.67, a current ratio of 0.89 and a debt-to-equity ratio of 0.47.

Astrazeneca (NYSE:AZN – Get Free Report) last issued its quarterly earnings data on Monday, July 27th. The company reported $2.63 EPS for the quarter, topping the consensus estimate of $2.50 by $0.13. Astrazeneca had a net margin of 17.02% and a return on equity of 31.45%. The business had revenue of $15.38 billion during the quarter, compared to analyst estimates of $15.44 billion. During the same period in the prior year, the business earned $2.17 EPS. The company’s revenue for the quarter was up 6.4% on a year-over-year basis. As a group, research analysts predict that Astrazeneca Plc will post 9.34 EPS for the current year.

Astrazeneca Profile

(Free Report)

AstraZeneca plc is a global biopharmaceutical company focused on the discovery, development and commercialization of prescription medicines. Its principal therapeutic areas include oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology conditions, and rare diseases.

The company’s portfolio includes medicines such as Tagrisso, Imfinzi and Lynparza for cancer; Farxiga for cardiovascular, kidney and metabolic conditions; Fasenra for severe asthma; and Symbicort for respiratory disease.